ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
Validation of proxy-reported EQ-5D-Y-3L in younger children with spinal muscular atrophy: age-related differences in performance.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to examine the psychometric performance of the proxy-reported EQ-5D-Y-3L (Y-3L) for children living with spinal muscular atrophy (SMA) aged between 5 and 12 years, with a particular focus on examining whether its properties differ across three age groups.
methodsPatients were recruited through a nation-wide patient advocacy association in China. Parents of eligible patients were invited to complete a web-based survey. Proxy-reported cross-sectional data from children aged 5-12 years were included in the analysis and categorized into three age groups: 5-6, 7-8, and 9-12 years. Convergent validity, known-groups validity, and the explanatory power of the Y-3L were assessed across the three age groups as well as in the overall sample.
resultsThe Y-3L showed strong ceiling effects for "pain/discomfort" and "feeling worried, sad, or unhappy," and floor effects in the three physical dimensions. Ceiling effects generally decreased with age for "pain/discomfort" and "feeling worried, sad, or unhappy." Level sum scores and index values correlated moderately to strongly with other measures. Four dimensions correlated well with comparator scales, but "doing usual activities" showed weaker links. Known-groups validity was highest for Y-3L, with clear age differences. Y-3L dimensions explained less EQ VAS variance with age, while emotional problems were more influential in 5-6-year-olds.
conclusionThe Y-3L is a valid instrument for assessing health-related quality of life in SMA children aged between 5 and 12 years, with better psychometric properties observed in older children aged over 7 years.
Indexed as
Identifiers
42613549What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.